320 Wakara Way
Salt Lake City
801 584 3600
Myriad Genetics is a leading biopharmaceutical company focused on the development of novel healthcare products. The Company markets molecular diagnostic tests to determine the risk of breast cancer, ovarian cancer, colon cancer, endometrial cancer and melanoma skin cancer in individuals with a family history of cancer.
- Myriad Genetics Announces New Executive Vice President of International Operations
- Myriad Genetics Elects Former Roche Molecular Systems CEO Heiner Dreismann to Its Board of Directors
- Myriad Genetics Announces New, Convenient OnDose(TM) Sampling Kit
- Myriad Study Shows PTEN Gene is Useful in Predicting Prostate Cancer Recurrence